Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Smith & Nephew SNATS Inc (NYSE:SNN) stock reached a 52-week high of 31.72 USD, marking a significant milestone for the company. This achievement reflects a 10.35% increase over the past year, showcasing the company’s positive performance and investor confidence. The stock’s climb to this 52-week high underscores the ongoing strength in Smith & Nephew (LON:SN)’s market position, as it continues to navigate the complexities of the healthcare sector. Investors will be closely watching to see if this momentum can be sustained in the coming months.
In other recent news, Smith & Nephew reported a solid start to 2025 with a first-quarter revenue of $1,407 million, reflecting a 1.6% increase from the previous year. The company’s underlying revenue growth was 3.1%, despite challenges from foreign exchange impacts and market conditions in China. Orthopaedics and Advanced Wound Management segments showed notable growth, driven by improvements in US Hip and Knee Implants and product launches. In analyst updates, Canaccord Genuity raised its price target for Smith & Nephew to $28 while maintaining a Hold rating, citing solid first-quarter results. Conversely, HSBC downgraded the company’s stock from Buy to Hold, reducing the price target to GBP10.70, acknowledging the potential of a new 12-point program but noting challenges in the US market. Additionally, Smith & Nephew announced the appointment of David King as an independent Non-Executive Director, effective July 1, 2025. David King brings extensive experience from his roles at Fortis (NYSE:FTS) Life Sciences and other healthcare companies. Smith & Nephew also plans to release its second-quarter and half-year 2025 financial results on August 5, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.